ID

38698

Descrição

Study ID: 101468/191 Clinical Study ID: SKF-101468/191 Study Title:A 12 Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS) Suffering from Periodic Leg Movements of Sleep (PLMS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication: Restless Legs Syndrome

Palavras-chave

  1. 08/09/2017 08/09/2017 -
  2. 30/10/2019 30/10/2019 - Sarah Riepenhausen
Titular dos direitos

GlaxoSmithKline

Transferido a

30 de outubro de 2019

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 3.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

GSK Ropinirole in Subjects with Restless Legs Syndrome 101468/191 Follow-up (Form 20)

GSK Ropinirole in Subjects with Restless Legs Syndrome 101468/191 Week 2 (Form 5)

General Information
Descrição

General Information

Center Number
Descrição

Center Number

Tipo de dados

integer

Patient Number
Descrição

Patient Number

Tipo de dados

integer

Patient Initials
Descrição

Patient Initials

Tipo de dados

text

Visit Date
Descrição

Visit Date

Tipo de dados

date

RLS rating scale
Descrição

RLS rating scale

Please complete the appropriate RLS Rating Scale from the RLS Rating Scale Book.
Descrição

RLS rating scale

Tipo de dados

text

Vital signs
Descrição

Vital signs

Pulse (after 5 minutes sitting)
Descrição

Pulse

Tipo de dados

integer

Unidades de medida
  • beats/min
beats/min
Sitting blood pressure systolic (after 5 minutes sitting)
Descrição

Sitting blood pressure (systolic)

Tipo de dados

integer

Sitting blood pressure diastolic (after 5 minutes sitting)
Descrição

Sitting blood pressure (diastolic)

Tipo de dados

text

Please record any medical procedures performed since the last visit in the Medical Procedures section at the back of this book.
Descrição

Medical Procedures

Tipo de dados

text

Please record any medical procedures performed since the last visit in the Concomitant Medication section at the end of this book.
Descrição

Concomitant Medication

Tipo de dados

text

Please record any adverse experiences observed or elicited by the following direct question to the patient: "Have you felt different in any way since the last visit?" in the Adverse Experience and/or SAE section at the back of this book.
Descrição

Adverse Experiences

Tipo de dados

text

Laboratory Evaluation
Descrição

Laboratory Evaluation

Date of blood sample
Descrição

Please take a blood and/or urine sample if any abnormality was detected at the final on therapy visit or at withdrawal.

Tipo de dados

date

Were any clinically significant abnormalities detected?
Descrição

Significant abnormalities

Tipo de dados

text

Investigational product and compliance record
Descrição

Investigational product and compliance record

Investigational Prod. Week No.
Descrição

Investigational Prod. Week No.

Tipo de dados

text

Is this a Dose Reduction?
Descrição

Is this a Dose Reduction?

Tipo de dados

text

Dose Level (specify 1-8)
Descrição

Dose Level

Tipo de dados

integer

Date of first dose
Descrição

Date

Tipo de dados

date

Number of tablets dispensed
Descrição

Number of tablets dispensed

Tipo de dados

float

Number of tablets returned
Descrição

Number of tablets returned

Tipo de dados

float

Investigational product interruption
Descrição

Investigational product interruption

To be completed at the Week 6 visit: Was dosing of investigational product interrupted for > 2 consecutive days during the week prior to visit 6?
Descrição

week 6: investigational product interrupted

Tipo de dados

boolean

To be completed at the Week 12 visit: Was dosing of investigational product interrupted for > 2 consecutive days during the week prior to visit 12?
Descrição

week 12: investigational product interrupted

Tipo de dados

boolean

To be completed at the Early Withdrawal visit: Was dosing of investigational product interrupted for > 2 consecutive days during the week prior to the Early Withdrawal ?
Descrição

Early Withdrawal visit: investigational product interrupted

Tipo de dados

text

Dose reduction due to adverse experiences
Descrição

Dose reduction due to adverse experiences

Study Visit Week (Specify)
Descrição

Study Visit Week

Tipo de dados

integer

Dose Level (specify)
Descrição

Dose Level

Tipo de dados

integer

Date of first dose
Descrição

Date of first dose

Tipo de dados

date

Date of Last Dose
Descrição

Date of Last Dose

Tipo de dados

date

Number of tablets dispensed
Descrição

Number of tablets dispensed

Tipo de dados

integer

Number of tablets returned
Descrição

Number of tablets returned

Tipo de dados

integer

Medical Procedures
Descrição

Medical Procedures

Have any non-medication, therapeutic, diagnostic or surgical procedures been performed since the last clinic visit (non-PSG)? All indications for procedures should be recorded in the Adverse Experience and/or SAE section as appropriate.
Descrição

Medical Procedures

Tipo de dados

text

Specification of Medical Procedures
Descrição

Specification of Medical Procedures

Procedure
Descrição

Procedure

Tipo de dados

text

Indication
Descrição

Indication

Tipo de dados

text

Procedure Start Date
Descrição

Procedure Start Date

Tipo de dados

date

Procedure End Date
Descrição

Procedure End Date

Tipo de dados

date

Concomitant Medication
Descrição

Concomitant Medication

Information
Descrição

Mark box below or complete page with concomitant medication details. Any new medical illness/diagnosis (or symptoms in the absence of a diagnosis) should be recorded on the Adverse Experience and/or SAE sections using the same terminology. If any medication was marked "Continuing" at a previous visit, but has since has a dosage change or has been stopped, it must be recorded as a change below with the new start and end date.

Tipo de dados

text

No new or change in concomitant medication since the previous visit.
Descrição

New or change in concomitant medication

Tipo de dados

boolean

Specification of Concomitant Medication
Descrição

Specification of Concomitant Medication

Drug Name (Trade Name Preferred)
Descrição

Drug Name

Tipo de dados

text

Total Daily Dose (e.g 500 mg)
Descrição

Total Daily Dose

Tipo de dados

float

Unidades de medida
  • mg
mg
Medical Illness / Diagnosis (or symptom in absence of diagnosis)
Descrição

Medical Illness / Diagnosis

Tipo de dados

text

Start Date (be as precise as possible)
Descrição

Start Date

Tipo de dados

date

End Date (or if Continuing mark box below)
Descrição

End Date

Tipo de dados

date

Continuing
Descrição

Continuing

Tipo de dados

boolean

Adverse Experiences (Non-Serious)
Descrição

Adverse Experiences (Non-Serious)

No adverse experiences occured during the study
Descrição

No adverse experiences occured during the study

Tipo de dados

boolean

Specification of Adverse Experiences (Non-Serious)
Descrição

Specification of Adverse Experiences (Non-Serious)

Onset Date and Time
Descrição

Onset Date and Time

Tipo de dados

datetime

End Date and Time (if ongoing please leave blank)
Descrição

End Date and Time

Tipo de dados

datetime

Outcome
Descrição

Outcome

Tipo de dados

text

Experience Course
Descrição

Experience Course

Tipo de dados

text

If experience course intermittend, please fill in number of episodes
Descrição

Number of episodes

Tipo de dados

integer

Intensity (maximum)
Descrição

Intensity (maximum)

Tipo de dados

text

Action Taken with Respect to Investigational Drug
Descrição

Action Taken with Respect to Investigational Drug

Tipo de dados

text

Relationship to Investigational Drug
Descrição

Relationship to Investigational Drug

Tipo de dados

text

Corrective Therapy
Descrição

Corrective Therapy

Tipo de dados

text

Was patient withdrawn due to this specific AE?
Descrição

Withdrawal

Tipo de dados

boolean

Pregnancy Information
Descrição

Pregnancy Information

Didi the patient become pregnant during the study?
Descrição

Pregnancy information

Tipo de dados

text

Study Conclusion
Descrição

Study Conclusion

Did the patient complete the study according to the protocol?
Descrição

Completion

Tipo de dados

text

Reason for withdrawal
Descrição

Reason for withdrawal

Tipo de dados

text

If other reason for withdrawal, please specify
Descrição

Specification of other reason for withdrawal

Tipo de dados

text

Investigator signature: I certify that I have reviewed the data in this Case Report Form, including laboratory data and that in the Adverse Experience and Serious Adverse Experience sections (if appropriate) and that all information is complete and accurate.
Descrição

Investigator signature

Tipo de dados

text

Date
Descrição

Date

Tipo de dados

date

Similar models

GSK Ropinirole in Subjects with Restless Legs Syndrome 101468/191 Week 2 (Form 5)

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
General Information
Center Number
Item
Center Number
integer
Patient Number
Item
Patient Number
integer
Patient Initials
Item
Patient Initials
text
Visit Date
Item
Visit Date
date
Item Group
RLS rating scale
RLS rating scale
Item
Please complete the appropriate RLS Rating Scale from the RLS Rating Scale Book.
text
Item Group
Vital signs
Pulse
Item
Pulse (after 5 minutes sitting)
integer
Sitting blood pressure (systolic)
Item
Sitting blood pressure systolic (after 5 minutes sitting)
integer
Sitting blood pressure (diastolic)
Item
Sitting blood pressure diastolic (after 5 minutes sitting)
text
Medical Procedures
Item
Please record any medical procedures performed since the last visit in the Medical Procedures section at the back of this book.
text
Concomitant Medication
Item
Please record any medical procedures performed since the last visit in the Concomitant Medication section at the end of this book.
text
Adverse Experiences
Item
Please record any adverse experiences observed or elicited by the following direct question to the patient: "Have you felt different in any way since the last visit?" in the Adverse Experience and/or SAE section at the back of this book.
text
Item Group
Laboratory Evaluation
Date of blood sample
Item
Date of blood sample
date
Item
Were any clinically significant abnormalities detected?
text
Code List
Were any clinically significant abnormalities detected?
CL Item
No (1)
CL Item
Yes -> If "Yes", please record details in the Adverse Experiences and/or SAE section at the back of this book. (2)
Item Group
Investigational product and compliance record
Investigational Prod. Week No.
Item
Investigational Prod. Week No.
text
Item
Is this a Dose Reduction?
text
Code List
Is this a Dose Reduction?
CL Item
No -> if "No", continue (1)
CL Item
Yes -> if "Yes", please complete the Dose Reductions due to AE on page 60. Do not continue on this page for this visit. (2)
Dose Level
Item
Dose Level (specify 1-8)
integer
Date
Item
Date of first dose
date
Number of tablets dispensed
Item
Number of tablets dispensed
float
Number of tablets returned
Item
Number of tablets returned
float
Item Group
Investigational product interruption
week 6: investigational product interrupted
Item
To be completed at the Week 6 visit: Was dosing of investigational product interrupted for > 2 consecutive days during the week prior to visit 6?
boolean
week 12: investigational product interrupted
Item
To be completed at the Week 12 visit: Was dosing of investigational product interrupted for > 2 consecutive days during the week prior to visit 12?
boolean
Item
To be completed at the Early Withdrawal visit: Was dosing of investigational product interrupted for > 2 consecutive days during the week prior to the Early Withdrawal ?
text
Code List
To be completed at the Early Withdrawal visit: Was dosing of investigational product interrupted for > 2 consecutive days during the week prior to the Early Withdrawal ?
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not Applicable (3)
Item Group
Dose reduction due to adverse experiences
Study Visit Week
Item
Study Visit Week (Specify)
integer
Dose Level
Item
Dose Level (specify)
integer
Date of first dose
Item
Date of first dose
date
Date of Last Dose
Item
Date of Last Dose
date
Number of tablets dispensed
Item
Number of tablets dispensed
integer
Number of tablets returned
Item
Number of tablets returned
integer
Item Group
Medical Procedures
Item
Have any non-medication, therapeutic, diagnostic or surgical procedures been performed since the last clinic visit (non-PSG)? All indications for procedures should be recorded in the Adverse Experience and/or SAE section as appropriate.
text
Code List
Have any non-medication, therapeutic, diagnostic or surgical procedures been performed since the last clinic visit (non-PSG)? All indications for procedures should be recorded in the Adverse Experience and/or SAE section as appropriate.
CL Item
No (1)
CL Item
Yes -> If "Yes", please record details below using standard medical terminology. (2)
Item Group
Specification of Medical Procedures
Procedure
Item
Procedure
text
Indication
Item
Indication
text
Procedure Start Date
Item
Procedure Start Date
date
Procedure End Date
Item
Procedure End Date
date
Item Group
Concomitant Medication
Information
Item
Information
text
New or change in concomitant medication
Item
No new or change in concomitant medication since the previous visit.
boolean
Item Group
Specification of Concomitant Medication
Drug Name
Item
Drug Name (Trade Name Preferred)
text
Total Daily Dose
Item
Total Daily Dose (e.g 500 mg)
float
Medical Illness / Diagnosis
Item
Medical Illness / Diagnosis (or symptom in absence of diagnosis)
text
Start Date
Item
Start Date (be as precise as possible)
date
End Date
Item
End Date (or if Continuing mark box below)
date
Continuing
Item
Continuing
boolean
Item Group
Adverse Experiences (Non-Serious)
No adverse experiences occured during the study
Item
No adverse experiences occured during the study
boolean
Item Group
Specification of Adverse Experiences (Non-Serious)
Onset Date and Time
Item
Onset Date and Time
datetime
End Date and Time
Item
End Date and Time (if ongoing please leave blank)
datetime
Item
Outcome
text
Code List
Outcome
CL Item
Resoved (1)
CL Item
Ongoing (2)
CL Item
Died (If patient died, STOP: go to SAE section and follow instructions given there) (3)
Item
Experience Course
text
Code List
Experience Course
CL Item
Intermittend -> please fill in No. of episodes below. (1)
CL Item
Constant (2)
Number of episodes
Item
If experience course intermittend, please fill in number of episodes
integer
Item
Intensity (maximum)
text
Code List
Intensity (maximum)
CL Item
Mild (1)
CL Item
Moderate (2)
CL Item
Severe (3)
Item
Action Taken with Respect to Investigational Drug
text
Code List
Action Taken with Respect to Investigational Drug
CL Item
None (1)
CL Item
Dose reduced (2)
CL Item
Dose increased (3)
CL Item
Drug interrupted/restarted (4)
CL Item
Drug stopped (5)
Item
Relationship to Investigational Drug
text
Code List
Relationship to Investigational Drug
CL Item
Related (1)
CL Item
Possibly related (2)
CL Item
Probably unrelated (3)
CL Item
Unrelated (4)
Item
Corrective Therapy
text
Code List
Corrective Therapy
CL Item
No (1)
CL Item
Yes -> If "Yes", record details in the Concomitant Medication section and/or Medical Procedures section if appropriate. (2)
Withdrawal
Item
Was patient withdrawn due to this specific AE?
boolean
Item Group
Pregnancy Information
Item
Didi the patient become pregnant during the study?
text
Code List
Didi the patient become pregnant during the study?
CL Item
Not applicable (not of childbearing potential or male) (1)
CL Item
No (2)
CL Item
Yes -> If "Yes" record details on Pregnancy Notification Form (3)
Item Group
Study Conclusion
Item
Did the patient complete the study according to the protocol?
text
Code List
Did the patient complete the study according to the protocol?
CL Item
Yes (1)
CL Item
No -> If "No" please mark the primary cause of withdrawal below. (2)
Item
Reason for withdrawal
text
Code List
Reason for withdrawal
CL Item
Adverse experience (please complete AE page) (1)
CL Item
Insufficient therapeutic effect  (2)
CL Item
Protocol deviation (including non-compliance) (3)
CL Item
Lost to follow-up (4)
CL Item
Other (please specify below) (5)
Specification of other reason for withdrawal
Item
If other reason for withdrawal, please specify
text
Investigator signature
Item
Investigator signature: I certify that I have reviewed the data in this Case Report Form, including laboratory data and that in the Adverse Experience and Serious Adverse Experience sections (if appropriate) and that all information is complete and accurate.
text
Date
Item
Date
date

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial